Where does Ambagon Therapeutics's cap table come from?

Share classes are assembled from certificates of incorporation, priced-round filings, and disclosures across Ambagon Therapeutics's 3 recorded funding rounds.

Premier Alternatives

Ambagon Therapeutics

Drug Discovery · Eindhoven, Netherlands · Founded 2019 · Privately Held (backing)

Developer of small-molecule cancer drugs designed to stabilize the direct interaction of oncogenic proteins. Ambagon Therapeutics is based in Eindhoven, Netherlands and was founded in 2019. It has raised $108 million across 3 recorded rounds; the latest was a $5 million early-stage round in Jan 2025.

Last price · $/share

—

Implied valuation

—

Total raised

$108.0M

Last round

Early Stage VC

Jan 2025

Cap table — not yet on record

Ambagon Therapeutics's share-class structure hasn't surfaced in our sources yet. Cap tables are assembled from certificates of incorporation, round filings, and disclosures as they land.

Pro members can request priority coverage with a 48-hour turnaround.

Free account

More of Ambagon Therapeutics with a free account

·The complete investor list: 13 names
·Watch Ambagon Therapeutics: the Monday email on marks, rounds and moves

Create free account

No card required

Membership and data by Private Market View

Frequently asked about Ambagon Therapeutics

Where does Ambagon Therapeutics's cap table come from?: Share classes are assembled from certificates of incorporation, priced-round filings, and disclosures across Ambagon Therapeutics's 3 recorded funding rounds.